TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15037271
Drug: Diltiazem (0.05‐0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.05‐0.1 mg/kg per hour)
Study: 9390110
Drug: Nitroglycerin (0.83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.83 mg/hr for 7 days)
Study: 3283777
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline ('Trental') 3-times daily
Study: 3283777
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg cinnarizine 3-times daily
Study: 3283777
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline ('Trental')
Study: 3283777
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg cinnarizine
Study: 23565616
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment with telbivudine
Study: 17241768
Drug: Functional voice
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional voice therapy
Study: 17120738
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin 400 mg once a day for 7 to 14 days
Study: 17120738
Drug: Cefoperazone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 2.0 g twice a day and azithromycin 0.5 g once a day for 7 to 14 days
Study: 17120738
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin 400 mg once a day
Study: 17120738
Drug: Cefoperazone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone 2.0 g twice a day and azithromycin 0.5 g once a day
Study: 10952121
Drug: Platinum/paclitaxel combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum/paclitaxel combination chemotherapy
Study: 10952121
Drug: Cisplatin/cyclophosphamide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/cyclophosphamide combination chemotherapy
Study: 9085457
Drug: Ethanol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.15 g/kg and 0.45 g/kg)
Study: 7524382
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with lidocaine (1 mg/kg) combined with moradol (0.005 mg/kg)
Study: 7524382
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with lidocaine (1 mg/kg) combined with morphine (0.01 mg/kg)
Study: 20166163
Drug: Radiant infrared
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiant infrared (IR) light emitting diode (LED) (970 nm) pre-treatment for 15 minutes
Study: 20166163
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no IR pre-treatment)
Study: 20166163
Drug: Radiant IR
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiant IR pre-treatment
Study: 12423433
Drug: Acitretin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (25 mg daily or on alternate days)
Study: 10509496
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (n=48)
Study: 1726521
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid with UVB therapy
Study: 1726521
Drug: Indifferent ointment
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indifferent ointment (control) with UVB therapy
Study: 30046129
Drug: Amoxicillin-Clavulanic Acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-Clavulanic Acid
Study: 9814469
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) at doses of 40 mg, 20 mg, and 10 mg
Study: 9814469
Drug: Subcutaneous testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous testosterone implant (100 mg)
Study: 9814469
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery system (TD1, TD2, TD3)
Study: 7662600
Drug: Nicorandil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (20 mg single oral dose)
Study: 7662600
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) (20 mg single oral dose)
Study: 7662600
Drug: Nicorandil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (2 x 20 mg/day for 8 days)
Study: 7662600
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) (3 x 20 mg/day for 8 days)
Study: 7662600
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) (2 x 20 mg/day for 8 days)
Study: 2727638
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg bacampicillin
Study: 2727638
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg amoxycillin
Study: 2727638
Drug: Omeprazole (potent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (potent acid inhibitor) pretreatment
Study: 796645
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (1500 mg/day)
Study: 28720233
Drug: Reflexology (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology (20 min, twice a week for 24 sessions)
Study: 23619129
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure (BP) treatment in treated patients (n=16)
Study: 23619129
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure (BP) treatment
Study: 17944981
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times a week for 4 weeks
Study: 9616526
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prednisolone for 3 weeks
Study: 31802716
Drug: Intravenous thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thyroxine (T4) infusion for 8 hours
Study: 31802716
Drug: No T4
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No T4 infusion (control)
Study: 31802716
Drug: Intravenous thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thyroxine (T4) infusion for 8 hours (in donors with a history of drug use)
Study: 31802716
Drug: No T4
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No T4 infusion (control) (in donors without a history of drug use)
Study: 27624670
Drug: Clofarabine 20
Normalized name: clofarabine 20 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine 20 mg/m2 for 5 days with daunorubicin
Study: 25098701
Drug: Bevacizumab combination
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combination therapy
Study: 19615130
Drug: Continuous high-volume
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-volume hemofiltration (HVHF) at 6 L/h for 24 hours
Study: 19615130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HVHF treatment)
Study: 15614149
Drug: Valganciclovir or
Normalized name: valganciclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir or oral ganciclovir prophylaxis for 100 days
Study: 2312776
Drug: conventional metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional metoprolol 50 mg tablets
Study: 23406320
Drug: High-dose intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intradermal (ID) vaccine
Study: 23406320
Drug: Standard-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intramuscular (IM) vaccine
Study: 7995187
Drug: Loperamide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide treatment
Study: 26633243
Drug: Self-administered taste
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered taste test using 'Taste Strips' (mean score 12.3 ± 2.6)
Study: 26633243
Drug: Examiner-administered taste
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Examiner-administered taste test using 'Taste Strips' (mean score 11.6 ± 2.6)
Study: 24146170
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once weekly with calcium and vitamin D supplementation
Study: 23343671
Drug: Protein Blend
Normalized name: Nutritional Supplement Oral Powder for Suspension [IMMUNE SUPPORT PROTEIN BLEND]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein Blend (PB) - ∼19 g
Study: 23343671
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein (WP) - ∼18 g
Study: 16717293
Drug: Cetuximab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (initial dose 400 mg/m2, subsequent weekly doses 250 mg/m2) in combination with cisplatin (100 mg/m2) and fluorouracil (FU) (escalating doses of 600, 800, and 1,000 mg/m2/d)
Study: 16717293
Drug: Cetuximab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (initial dose 400 mg/m2, subsequent weekly doses 250 mg/m2) in combination with carboplatin (AUC 5) and fluorouracil (FU) (escalating doses of 600, 800, and 1,000 mg/m2/d)
Study: 16717293
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (cetuximab, cisplatin/carboplatin, and FU)
Study: 11737876
Drug: UVA irradiation
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA irradiation administered with an air-conditioned sunbed, cumulative UVA dose: 96 J/cm2, two exposures weekly for three weeks
Study: 9240635
Drug: Helium-Neon laser
Normalized name: neon
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium-Neon laser treatment (632.8 nm wavelength, power 60 mW), applied daily from d-5 to d-1 on five anatomic sites of the oral mucosa.
Study: 8260235
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with BCNU 80 mg/m2 i.v. every 4 weeks, actinomycin-D 10 micrograms/kg, vincristine 1.0 mg/m2 i.v. every 2 weeks for 6 months
Study: 3653755
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension during fasting
Study: 3653755
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension postprandially
Study: 31668839
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus oxaliplatin (GEMOX) - gemcitabine 1000 mg/m2, oxaliplatin 100 mg/m2 on day 1 every 2 weeks
Study: 31668839
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus carboplatin (GCb) - gemcitabine 1000 mg/m2 on day 1 and day 8, carboplatin AUC 4.5 mg/mL/min on day 1 every 3 weeks
Study: 29902447
Drug: Belladonna and
Normalized name: BELLADONNA AND DERIVATIVES, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belladonna and opiate suppository (16.2/7.5 mg)
Study: 27067068
Drug: Cognitive-behavioral intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral intervention (N = 88), administered in five weekly 90-min sessions.
Study: 10534248
Drug: BoNT/B (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/B (both doses)
Study: 7092498
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of DE gamma E intramuscularly (IM) daily for ten days
Study: 7092498
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of DE gamma E intramuscularly (IM) daily for ten days
Study: 7092498
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of DE gamma E IM daily for ten days
Study: 20473735
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg once a day)
Study: 23011378
Drug: Clarithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (250 mg/day for 3 months) with topical corticosteroid treatment
Study: 19605972
Drug: First-line drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line drugs (benzodiazepines: lorazepam, diazepam)
Study: 19605972
Drug: Second-line drugs
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line drugs (phenytoin, fosphenytoin)
Study: 19605972
Drug: Refractory status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refractory status epilepticus treatments (barbiturates: phenobarbital, pentobarbital, thiopental; valproate; midazolam; propofol; isoflurane)
Study: 14994883
Drug: Headgear (HG)
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headgear (HG) treatment for 16 months
Study: 10634841
Drug: 4% amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% amethocaine gel (Ametop)
Study: 11352393
Drug: E45 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: E45 cream (placebo)
Study: 8204495
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 80 micrograms/kg
Study: 8204495
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 80 micrograms/kg plus butorphanol 40 micrograms/kg
Study: 28318984
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus neurovascular thrombectomy (Solitaire FR)
Study: 25486372
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and Sertraline (COMB)
Study: 23390005
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management with pill placebo (PBO)
Study: 22935042
Drug: Extra protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra protein (33 g whey protein/day)
Study: 22935042
Drug: Fast-food meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-food meal (1350 kcal, 41 g protein)
Study: 17543376
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 18 months
Study: 11475558
Drug: Serum antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum antibodies against 38 kDa
Study: 11475558
Drug: Serum antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum antibodies against 38 kDa and ACE activity
Study: 9806257
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg per day Org OD 14 (tibolone) for 3 months
Study: 9806257
Drug: Placebo (multi-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multi-vitamin pill) for 3 months
Study: 2529112
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy (0.2 mg/kg)
Study: 2529112
Drug: Intra-arterial (0.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial (0.21 mg/kg) plus intravenous (0.09 mg/kg) therapy
Study: 18632013
Drug: Lifestyle interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle interventions and medication
Study: 9728851
Drug: Large-dose esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose esmolol (250 microg x kg(‐1) x min(‐1)) with isoflurane
Study: 9728851
Drug: Alfentanil (effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (effect site target of 50 ng/mL) with isoflurane
Study: 9728851
Drug: Alfentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil with small-dose esmolol (50 microg x kg(‐1) x min(‐1))
Study: 9728851
Drug: Alfentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil with large-dose esmolol
Study: 9419752
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen patch (TE2)
Study: 9419752
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen patch with added medroxyprogesterone acetate (TE2/MPA)
Study: 55780
Drug: Oxprenolol (≤320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (≤320 mg/day, increased to 960 mg if inadequate response)
Study: 55780
Drug: Methyldopa (≤1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (≤1 g/day, increased to 3 g if inadequate response)
Study: 30852482
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg, 1 time/day
Study: 26199710
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered IV midazolam (0.5 mg/kg for children under 5 years, 0.2 mg/kg for patients over 5 years)
Study: 26199710
Drug: Commercially prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially prepared midazolam syrup
Study: 26199710
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (IV/Oral and syrup)
Study: 1794157
Drug: Continuous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous or unequal day-night terbutaline dosing (initial bolus doses of 1.47, 2.94, and 4.41 micrograms/kg)
Study: 18996742
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem (10mg)
Study: 18996742
Drug: Oral zolpidem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zolpidem (10mg)
Study: 16999754
Drug: Postoperative autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative autologous blood re-infusion system 1
Study: 16999754
Drug: Postoperative autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative autologous blood re-infusion system 2
Study: 16999754
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no re-infusion)
Study: 14532838
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (TCl) 10, 15, 20, or 25 mg daily for 21 days
Study: 10897047
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen of doxorubicin and CMF
Study: 6378743
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN (isosorbide dinitrate) acute administration
Study: 6378743
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN (isosorbide dinitrate) during long-term treatment
Study: 6378743
Drug: Control values
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control values during long-term treatment
Study: 24597620
Drug: Secukinumab 25
Normalized name: secukinumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 25 mg, 75 mg, 150 mg, 300 mg
Study: 24597620
Drug: Secukinumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (all dose groups combined)
Study: 20068568
Drug: Cetuximab 400
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m² at first infusion followed by weekly infusions of 250 mg/m² combined with FUFOX (oxaliplatin 50 mg/m², 5-FU 2000 mg/m², and DL-folinic acid 200 mg/m²)
Study: 15826417
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 20 mg/kg on induction
Study: 6253122
Drug: Indomethacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (2 mg day‐1 kg‐1) given orally for 7 days
Study: 31902875
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg administered intravenously four times with an inter-dose interval of 2 weeks)
Study: 25845867
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg KAE609 plus 320 mg PPQ
Study: 25845867
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg KAE609 plus 1,280 mg PPQ
Study: 25845867
Drug: PPQ alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPQ alone (320 mg)
Study: 25845867
Drug: KAE609 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 alone (25 mg)
Study: 25845867
Drug: KAE609 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 and PPQ combination
Study: 20963449
Drug: Miglitol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (titrated from 50 mg to 100 mg 3 times daily)
Study: 19276198
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 6 mg of nicorandil
Study: 17113349
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 mg/day)
Study: 30919899
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril and telmisartan
Study: 15017470
Drug: Extended interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended interval dosing (EID) of gentamicin
Study: 15017470
Drug: Conventional interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional interval dosing (CID) of gentamicin